Winning
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If the military decides to pick up the pain device and incorporate it in their hospitals, keep in mind the military has the largest array of hospitals in the world. If this device can cut the military's cost of treating back problems for their enlisted men/women, their dependents, and their veteran's, I think it's safe to say they'd do it.
Selling for a loss today is just plain illogical. The odds of it being substantially higher by EOD tomorrow and Monday are very, very high. But, as the saying goes, 'They walk among us.'.
Who knows. But anytime I find myself thinking 'Why in the hell would a CEO do that? It's not logical", I refer back to what the CEO from POSC did last May during the Nasdaq Market Announcement debacle. My point is, nothing surprises me anymore when it comes to penny stock CEO's and their decision making process. For all I know he wanted the stock to look cheaper and more enticing for future investors. Probably thought it would look too high going into the WCD. Consolidate now instead of later. Ton of reasons to speculate on.
For a guy doing this for decades, he knows how a volatile market works. I think he has something good up his sleeve. I'm looking forward to the next 2 weeks. Who knows, maybe it gaps up tomorrow morning. :)
Give the guy some credit. At least he's still publicly filing everything. And with allit's been through, the company is still in operation. Weinbrandt is a very smart guy. Eventually, he will win. Even the LA Clippers will win a few. If you're invested in this company, however, grab a Snickers, you're gonna be a here a while. Cheers!
Ha! He's referring to people that buy high then sell low. They walk among us.
You just referred to the biggest question, in my eyes. What kind of deal is Marcus-EPGL-Military forging with that FDA approved pain device. Bigger question is, is the deal already forged? EPGL's wild card perhaps? WebMD will serve a different purpose, with regards to EPGL's publications.
If the military institutes this device at all of their hospitals, around the world then.....wow! Keep in mind the best medical technology seems to always be used by the military first. If the US military adapts it into their system, perhaps our allies are soon to follow.
Also,lets not forget about the magazine being put into different languages. Huge opportunity there, especially when dealing with worldly recognized issues. That'll be where WebMD steps in.
Hopefully, question marks will be turn into periods by this weekend.
Nobody can say for certain, now, what the next few days will bring.
It's still early yet, there could be another PR from the company today. They had to of known that PR would create a sell off. The Old Man has been around long enough to know that. This tells me that there's a chance that they are holding a wild card.
For those that bought at the 1's and the 2's and sold at the 5's and 4's, congrats on your profits! Especially for those that have done it twice now. Good play....gamble! There's still another opportunity to buy back in and I'm sure most of you will at the 2's and 3's. I don't see the 1's happening. Would have to see over 100mil of selling to have that happen and that won't occur on the heels of the WCD. I still have 100% of my position at 4. Personally, if it goes to 1, I can weather the loss. Selling for a meager profit at the 5 or 6's isn't worth my time, so I am holding. I think that for those that are in at the 3's and 4's, most feel the same way. We just have to wait a little longer.
As for the final verdict of the pps, the presentation by Dr. Marcus will be from 1:00pm to 1:50 pm, Dallas time, on Friday. The market will be closed before any viable info can come out from it. Who has the balls to hold over the weekend? Monday it will either hit or miss with investors. Then we have a shortened market week with Thanksgiving on top of that. By December 1st, the fog should be clear and we will have a full picture of what we are dealing with.
Win or lose or tie, I frigging love this game!!!!!!
Congrats to all of you that held through the turmoil of yesterday.
Wish I could of gotten my order filled. Better luck next time I guess. Cheers!
Not to bring up another company, but only to use as an example,
SLRW, yesterday, tanked hard to a new 20 day low, freaking out all investors causing a massive sell off. Today, it gapped up and is currently up over 130%. Everyone that sold on fear is kicking themselves right now.
Either that or just a typical quick 'bear raid'. Easy to do with a volatile stock by a just a few traders.
What can you do? Sometimes you win, sometimes you lose. Coulda been the 'all or nothing' I had selected. But, I got filled on another company that was very unlikely to happen, so it was a good day regardless. I frigging love this game.
I'll be back here tomorrow for round 2. :)
I had seperate buy orders in for 0013, 0014, 0015 and 0016 since 10am. Never got filled. Drats!!!
Notable Presentations over the past 3 months:
1. In November, NewCardio presented at Cambridge Healthtech Institute’s Mitigating Safety Risks in Early Clinical Development conference in Philadelphia. Presentations by NewCardio and others supported adopting automated algorithms for ECG analysis.
2. In October, NewCardio was invited by the FDA to present at the Diabetic Drug Safety Conference meeting entitled "Development of Type 2 Diabetes Mellitus Drugs: State-ofthe-Art Cardiovascular Safety Assessments" in Washington DC. Dr. Ihor Gussak’s
presentation, entitled "Quantitative 3-dimensional Electrocardiography Substantially Improves Diagnosis of Acute Coronary Syndromes in Type II Diabetic Patients,"
demonstrated that my3KG is 42% more accurate than the 12-lead ECG in diagnosing Acute Myocardial Infarction in diabetic patients, with equal or better specificity.
3. The August 2010 issue of Heart Rhythm published a study, entitled
"Vectorcardiographic and Electrocardiographic Criteria to Distinguish New and Old Left Bundle Branch Block." This study was performed by Beth Israel Deaconess Medical Center and the Harvard Clinical Research Institute, in collaboration with NewCardio.
Results demonstrated 100% sensitivity and 96% specificity in distinguishing old versus new left bundle branch block, which is an essential element in directing cardiac intervention.
Newcardio continues it's upward progress as results from the 3rd Quarter show.
1. Cash burn of $852,000 declined 43% as a result of the ongoing expense reduction initiative.
2. New Cardio has $1.0 million in cash, and has entered a $1.5 million line of credit from three current investors which becomes effective January 1. This liquidity and forecasted revenue can finance NWCI through 2011.
3. NewCardio reports that it continues to make progress toward securing strategic funding to accelerate development of CardioBip for remote ECG monitoring, and My3KG for heart attack detection in the hospital emergency department.
4. NewCardio has been invited by the FDA-affiliated Cardiac Safety Research Consortium (CSRC) to present QTinno performance in a blinded comparison with core laboratory results involving a recent Thorough QT study. The presentation is scheduled on December 9 at the FDA in Silver Springs, Maryland. NewCardio has not released this study’s outcome but management states that it is very pleased with the results and we are encouraged by NewCardio’s invitation to present at
this prominent forum.
5. The visibility and acceptance of automated ECG methodologies is gaining critical momentum. This is supported by the leading ECG core laboratory, which stated in November that customer inquiries into automated technologies are increasing and that it now offers an
automated solution. This is a significant change from this laboratory’s prior recommendationsagainst using automated technologies.
Well, that's where you have to have some faith in the old man. He's the only one at this point that can do something to get a tidal wave of new buyers in here. It's all on him from here on out. If the news/conference is mediocre or average, people will adhere to the 'sell on the news' trading philosophy. If it's exceeds expectations, then we could see some good action. Perhaps a gap or two.
Like in our discussion last week. This action is exactly what we thought it would be. That the 5's would come on decent volume, 100-200mill, but for 5's to become solidified and 6's to come and stay or break the wall, we'd have to have a couple days of monstrous volume of 500 mil, consisting of new investors buying the flipper's shares.
But regardless, this moving exactly the way it should be and as expected.
My thoughts are that 5's will come relatively soon on good volume. 100-200mil, but once the 5's do hit, we will need to see volume up over 500mil, over multiple days, just to hold it.
The flippers will all be selling when the bid hits 4. Being that they are the majority, it'll take a lot of new investors to keep this going. Hence, why I have such a big number in my head.
Personally, I'll sell a portion to cover my costs and then hold the rest with house money. I hold 4.5 million at 3.
Looking to get on this train.
Not sure yet. Basically, I got destroyed in another company that is going downhill fast and happens to now have the same pps as SLRW. Of course, I started the other company at .16. With what I have left,I need a company that is going to start the trek upwards. I start my DD on this one tonight. Will take me about 2 days to make an informed decision. I have a couple others to look at as well.
Is there anything about this company I should should look at first?
I have noticed something about an alliance with Matheson. I will be looking into that tonight. But anything that could give me a head start and help me save some time would be appreciated. Otherwise, I will get it all in due time.
Thanks and cheers,
~A
0815ax, We need to get some more eyes on this board.
NWCI Newcardio inc, Heavily accumulated leading up to conference call and upcoming news release regarding blind test with the Cardiac Safety Research Consortium. Currently working with Fredrick Frank to obtain partnerships and strategic alliances.
http://investorshub.advfn.com/boards/board.aspx?board_id=13573
St. George will most definitely continue lending to them. Helix has been their golden egg.
NWCI, with today's news, is on it's way to being a game changer.
http://investorshub.advfn.com/boards/board.aspx?board_id=13573
'NewCardio is the first automated cardiac safety solution to accept Cardiac Safety Consortium independent blinded analysis'
SANTA CLARA, CA (November 9, 2010) - PR Newswire - NewCardio, Inc. (OTC BB: NWCI), a cardiovascular diagnostic solutions developer, announced today that Dr. Samuel George, NewCardio's Senior Medical Advisor, will present the results of QTinno performance on a blinded "testing" dataset, conducted independently by the Cardiac Safety Research Consortium (CSRC), at the CSRC's Annual Meeting, to be held on December 9, 2010, at the headquarters of the Food and Drug Administration (FDA) in Silver Spring, MD.
At the meeting, Dr. George will present results of a blinded validation study in which CSRC-affiliated investigators independently evaluated the accuracy and precision of fully automated QTinno measurements in 11,672 electrocardiograms (ECGs) from the moxifloxacin and placebo arms of a recent Thorough QT Study (TQTS). In the study, the CSRC investigators made detailed comparisons of QTinno measurements to those originally submitted by the drug sponsor, with the primary comparators of accurate detection of the moxifloxacin effect on QT intervals.
The CSRC makes this blinded TQTS "testing" dataset available to automated cardiac safety technology solution providers, with the conditions that the blinded analysis is conducted independently by the CSRC without any company involvement, and that any (either favorable or unfavorable) results obtained will be made public. NewCardio is the first company which has agreed to these conditions and completed the evaluation.
Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "We are very proud to be the first automated cardiac safety solution to accept the rules of engagement defined by the CSRC for evaluating the performance of our automated solution, QTinno, utilizing the blinded CSRC 'testing' dataset. Our willingness to enter into this very important and strictly regulated validation study reflects our high level of confidence in the accuracy and precision of the fully automated ECG measurements provided by QTinno. Prior to this blinded CSRC validation study, we have validated QTinno extensively, in collaboration with partners from Pharma, Clinical Research Organizations, and Academia. In every one of these 9 validation studies performed to date, which included over 100,000 ECGs, QTinno has provided highly accurate, fully automated measurements with an average 19% reduction in QT/QTc measurement variability. Based on this consistent performance in prior studies, we are confident that QTinno will perform well in any head to head comparison with the current ECG analysis methodologies."
Must watch this video of Dr Norman Marcus regarding back pain.
Best news in a while!
NewCardio is the first automated cardiac safety solution to accept Cardiac Safety Consortium independent blinded analysis
SANTA CLARA, CA (November 9, 2010) - PR Newswire - NewCardio, Inc. (OTC BB: NWCI), a cardiovascular diagnostic solutions developer, announced today that Dr. Samuel George, NewCardio's Senior Medical Advisor, will present the results of QTinno performance on a blinded "testing" dataset, conducted independently by the Cardiac Safety Research Consortium (CSRC), at the CSRC's Annual Meeting, to be held on December 9, 2010, at the headquarters of the Food and Drug Administration (FDA) in Silver Spring, MD.
At the meeting, Dr. George will present results of a blinded validation study in which CSRC-affiliated investigators independently evaluated the accuracy and precision of fully automated QTinno measurements in 11,672 electrocardiograms (ECGs) from the moxifloxacin and placebo arms of a recent Thorough QT Study (TQTS). In the study, the CSRC investigators made detailed comparisons of QTinno measurements to those originally submitted by the drug sponsor, with the primary comparators of accurate detection of the moxifloxacin effect on QT intervals.
The CSRC makes this blinded TQTS "testing" dataset available to automated cardiac safety technology solution providers, with the conditions that the blinded analysis is conducted independently by the CSRC without any company involvement, and that any (either favorable or unfavorable) results obtained will be made public. NewCardio is the first company which has agreed to these conditions and completed the evaluation.
Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "We are very proud to be the first automated cardiac safety solution to accept the rules of engagement defined by the CSRC for evaluating the performance of our automated solution, QTinno, utilizing the blinded CSRC 'testing' dataset. Our willingness to enter into this very important and strictly regulated validation study reflects our high level of confidence in the accuracy and precision of the fully automated ECG measurements provided by QTinno. Prior to this blinded CSRC validation study, we have validated QTinno extensively, in collaboration with partners from Pharma, Clinical Research Organizations, and Academia. In every one of these 9 validation studies performed to date, which included over 100,000 ECGs, QTinno has provided highly accurate, fully automated measurements with an average 19% reduction in QT/QTc measurement variability. Based on this consistent performance in prior studies, we are confident that QTinno will perform well in any head to head comparison with the current ECG analysis methodologies."
Day 1 schedule of the Cambridge Healthtech Institute Drug Safety Conference
http://www.healthtech.com/Conferences_Overview.aspx?id=99576
That sounds great! Glad I was wrong.
Lets hope for the best.
No you didn't.
Most penny stock traders do not hold onto shares. 3 days is normally the maximum. If the stock does nothing in that time period, they move on to the next one. And they always have a next one waiting in the wings, so if they hold too long, they lose.
Its not that they don't believe the stock has potential, its just that they believe the stock doesn't have potential to make a big move at this moment. You can pretty much guarantee that this is on their watchlists.
In all, while we stay put and hold for the next leg up, they are making money in other stocks and will get back into this when their strategy indicates them to do so.
If I was an MM, there is no way in hell that I would raise the PPS at this point in time. With all the people willing to sell their shares at .0001, why would the MM loose out on that opportunity? The only way I would raise it up is when buying volume forces my hand. If news doesn't create buying pressure then news doesn't matter.
They are going to get as much as they can until the speculative buying begins as we approach November 17th. They will shoot this thing up when they're ready. I'm glad they are only allowing themselves to buy at .0001. The more they have, the less the guy who is going to sell at .0002 has. They are setting themselves up to make a fortune. The more they have at stake the higher they'll let the pps go up when they do decide to raise it.
The big question is how high up will they let it get before they cash in.
The question I have for Joe is when he plans on converting the 350,000. Will the conversion take place after the company has taken voting control over from the shareholders?
Until they lay out the schematics of the restructuring, this puppy is staying put. I thought the WCD would play a big role but I doubt it now. Its all about the restructure.
Actually, from what I've researched, their O/S is around 4.07-4.08 billion. Not 4.7 billion.
Iblong, I believe these are the answers Sue posted.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=55702043
Just giving out info. I've read earlier posts about questions regarding the patents. People can do with it what they want.
Intellectual Property information. This is taken from a 10K
The Company owns all rights, title and interest in one currently pending U.S. patent application, one currently pending Patent Cooperation Treaty (“PCT”) patent application, and two U.S. federal trademark registrations.
The U.S. and PCT patent applications both cover the same technology, namely vertical axis wind turbines with segmented Savonius rotors. The Savonius rotor is assembled by interlocking several relatively small and easily manageable individual blade segments. This unique segmented design has several advantages over traditional vertical axis wind turbine designs, including ease of manufacturing, ease of assembly, and suitability for residential use.
The U.S. patent application (serial no. 11/705,844) was filed on February 13, 2007 and first published on August 14, 2008 as U.S. patent application publication no. 2008/0191487. The application remains pending by the U.S. Patent Office. Assuming a patent is granted and that no patent term adjustments are made, the patent will expire on February 13, 2027.
The PCT patent application (serial no. PCT/US2008/001983) was filed on February 13, 2008 and claims priority to the Company’s U.S. patent application serial no. 11/704,844. The International Searching Authority issued a Written Opinion on July 1, 2008. Helix Wind responded to the Written Opinion on September 30, 2008. The application has not yet entered the national phase in any country, although Helix Wind may prosecute the application in all 138 PCT contracting states. The term of any patent that issues in a foreign country depends on the law of that country, but in general is 20 years from the filing date.
The Company owns U.S. federal trademark registration no. 3,524,780 for “HELIX WIND,” registered on October 28, 2008. The registration is due for renewal on October 28, 2018. Helix Wind also owns U.S. federal trademark registration no. 3,506,184 for “E2 ENERGY (R)EVOLUTION,” registered on September 23, 2008. The registration is due for renewal on September 23, 2018. Both of these U.S. federal trademark registrations are in International Class 007 for use in connection with “wind turbines and accessories for wind turbines.”
There hasn't been nearly enough volume to give MM's reason or justification to raise pps. There are hardly any buyers at .0003.
I'm sure that there are more buy orders at .0002 then .0003 right now. Raising it to.0004 or .0005 would pointless. Additionally, I would imagine that there are plenty of investors that have sell orders in at .0003 and .0004. I'm willing to bet that over half the investors in this company want out. Most sub penny stock investors never like to hold. That simple. Raising the pps a tick or two right now would create a massive sell off.
MM's have access to Level 3's. They can see all of the orders that are being placed. Right now,what they are seeing is telling them to keep the pps right where it is. They can see what investors want to do. When the investor decides to let this go up, the MM's will take it up. Also keep in mind, that even though 10-40 million in volume seems to be a lot, that's only 3 to 12 thousand dollars being traded. A quick uptick of 12 million like we saw earlier at .0002 or.0003, I don't recall what it went for, is only between 2400-3600$. Not nearly enough to justify a 33% increase in pps which is what one tick right now would be.
It will take a bare minimum of 80 million to kick start a pps increase. At least 250 million to get it back to .0004 bid or .0005 ask. Then it has to sustain itself, in which the penny flippers will do their best to not let that happen. With that said, we would need over 500 million volume to sustain the pps as the profit takers step in. It'll take more then a couple pieces of good news to do that. Right now, the Conference in November is the only entity that can do that, or perhaps some amazing restructuring deal being announced.
Until then this will remain in it's current range. Don't get me wrong, I do believe that MM's manipulate a ton of penny stocks. I don't trust them at all. But as a realist, I just don't see the MM's doing anything crazy right now with this one.
The company applied for patents in 2007 and they are expected shortly. With the turmoil that the US Patent Office is currently going through, regular patents take 4 to 5 years. However, Helix's patents are green energy patents, which mean they part of the USPTO's 'fast track' program where green energy patent applications take from 2 to 3 years for approval instead of the status quo. That being said, I think it's safe to say that we could see patent approval by the end of 2010.
The deal with VENCO is still up in the air. There has been nothing filed or said in recent news by Helix in regards to it other then that they are in negotiations. To read into it either way would just be guessing. Perhaps something will be said about it in the next 10Q. My correspondence with the CEO said he couldn't legally/ethically say anything about it. Which goes to say that negotiations still have a heart beat.
According to the last 8K the total OS is 435,794,365
Article regarding the medical device market.
US Medical Device Market to Reach $94.9 Billion in 2010
ROCKVILLE, MD--(Marketwire - October 19, 2010) - MarketResearch.com has announced the addition of Espicom Healthcare Intelligence's new report "The Medical Device Market: USA" to their collection of Medical Devices market reports. For more information, visit http://www.marketresearch.com/product/di...
With a population over 300 million, the USA is the third largest country in the world, behind China and India. The largest state is California, with a population of 37 million.
At an estimated US$94.9 billion in 2010, the US medical device market is the world's largest. Per capita expenditure, at US$306, is the third highest in the world.
Much of the market is in private hands; there is no single health system. Public healthcare systems, known as Medicaid, for those on low incomes, are operated by each State. Since 1960, the Medicare system has provided hospital care for the elderly; this has also provided prescription drug coverage since 2006.
President Obama succeeded in signing his healthcare reform bill into law on March 23rd, 2010. The bill, formally called the Patient Protection and Affordable Care Act HR 3590, will eventually extend health insurance cover to an estimated 32 million Americans who don't have any form of health insurance.
The USA is home to many of the world's leading medical device manufacturers, such as Johnson & Johnson, General Electric, Baxter, Covidien and Medtronic. Seven out of the world's top ten device manufacturers are US companies.
Imports are forming an increasingly significant part of the market, and now account for around 31% of the total. This growth is partly explained by US manufacturers using cheap locations abroad, such as Ireland or Mexico, in order to re-export to the US market.
The market is highly regulated, and can be an expensive one in which to operate. It is, however, transparent and 'rules-based.' The US is a major site for R&D and clinical trials.
For more information, visit http://www.marketresearch.com/product/di...
That's why I think it'll only hit the 'straight away' with the World Disability Conference. As of now that is the only entity that can create enough volume to force the MM's hands.
EPGL CEO interview posted by investment nation
http://investmentnation.com/
Interview now posted by EPGL
http://investmentnation.com/